Synopsis: Maruti Global Industries Limited has secured a Rs. 5.9 crore sub-contract work order from MSN Laboratories Private Limited for executing structural construction works at one of the pharmaceutical company’s projects. The order expands the company’s order book in the infrastructure construction segment and involves a wide range of civil, structural, fabrication and finishing works.
India’s pharmaceutical sector continues to invest in expanding manufacturing capacity to meet rising domestic and export demand. Such capacity additions create significant opportunities for engineering and construction companies involved in industrial buildings, manufacturing facilities and supporting infrastructure. Against this backdrop, Maruti Global Industries has secured a fresh construction contract from one of India’s leading pharmaceutical companies.
Shares of Maruti Global Industries Limited were trading at Rs 39.94, up by 1.99%. The stock opened at a day’s high of Rs 41.11 and has so far recorded a day’s low of Rs 39.94. The company’s current market capitalisation is Rs 20 crore, and it is trading at a P/E ratio of 27.7, which is higher than the industry peer median of 21.03
Maruti Global Wins Rs. 5.9 Crore Construction Contract
Maruti Global Industries Limited announced that it has received a subcontract work order worth approximately Rs. 5.9 crore from MSN Laboratories Private Limited for executing the construction of structural works, retaining walls, fabrication and other associated civil works.
The company stated that it received the order in the ordinary course of business and expects it to contribute positively to its operational performance. The contract has been awarded by a domestic entity, and the execution timeline will be governed by the terms specified in the work order.
Order Covers End-to-End Civil Construction Activities
Beyond the headline contract value, the attached work order provides a detailed scope of execution, indicating that Maruti Global will undertake multiple stages of industrial construction rather than a single activity.
The project includes earthwork and excavation, covering site cutting, trench excavation, foundation preparation, backfilling, anti-termite treatment and road formation. It also involves reinforced cement concrete (RCC) works, including foundations, columns, beams, slabs, retaining walls, machine foundations, pedestals and reinforced structural components required for an industrial facility.
The scope includes structural fabrication, masonry, brickwork, plastering, waterproofing, granite and vitrified tile flooring, doors, windows, ventilation systems, scaffolding, concrete repair, and finishing. The purchase order’s work schedule includes installation-related civil works, internal road development, drainage structures, and other finishing works needed for project completion.
The purchase order requires project consultants and site engineers to monitor measurements, billing, and execution against approved engineering drawings and quality standards. It includes performance clauses for execution quality, project timelines, and delay penalties, reflecting a structured engineering procurement and construction (EPC) execution framework.
Project Supports Expansion of Industrial Infrastructure
MSN Laboratories is one of the leading pharmaceutical manufacturers in India and expanding manufacturing footprint. Such construction contracts usually require specialised civil engineering for pharmaceutical production facilities where quality of work, structural stability and compliance with engineering specifications are critical.
Successful project execution for established pharma companies can enhance the company’s execution credentials and create opportunities to win additional contracts in sectors such as pharma, manufacturing, industrial infrastructure and commercial construction.
The order also reflects the diversified nature of Maruti Global’s construction capabilities, covering everything from site development and structural engineering to finishing works, all under a single contract.
Financial Highlight
The company reported a strong improvement in Q4 FY26 (March 2026) compared with Q3 FY26 (December 2025). Revenue surged 123.7% QoQ to Rs. 13.42 crore from Rs. 6.00 crore, driven by higher business activity. As operating expenses increased at a slower pace to Rs. 12.90 crore from Rs. 5.97 crore, financing profit jumped to Rs. 0.52 crore from Rs. 0.03 crore, while the financing margin improved sharply to 3.87% from 0.50%.
The improvement in operating performance translated into stronger profitability. Profit Before Tax (PBT) increased to Rs. 0.51 crore in Q4 FY26 from Rs. 0.02 crore in Q3 FY26, while net profit rose more than 25 times to Rs. 0.52 crore from Rs. 0.02 crore. Consequently, EPS strengthened significantly to Rs. 1.04 from Rs. 0.04, reflecting a sharp turnaround in earnings during the quarter.
The company maintains a relatively stable financial position with cash and cash equivalents of Rs. 0.66 crore and a current ratio of 1.43, while remaining debt-free and has generated a healthy ROCE of 69.6% and return on assets of 20.1%.
Although the company has a small market capitalisation of Rs. 20 crore, the latest quarter indicates a meaningful improvement in operational performance and profitability.
Strategic Insight and Industry Analysis
Although the Rs. 5.9 crore order is small, its significance lies in the scope of work involved, not mere contract size. The detailed scope suggests Maruti Global will participate in multiple project stages, maximising its civil engineering, fabrication, and construction capabilities. Integrated contracts help contractors build client relationships and increase their chances of getting expansion work.
Pharmaceutical manufacturing, industrial parks, and factory infrastructure investments in India should keep demand for specialised construction contractors high. Investors will likely watch the company’s project execution, order inflows, and ability to diversify and strengthen its industrial contracts.
Maruti Global Industries Limited (formerly Maruti Securities Limited) operates in the engineering, infrastructure and construction sector. The company undertakes civil construction, structural fabrication and industrial infrastructure projects, providing execution services across structural works, retaining walls, RCC construction, fabrication and allied engineering activities for industrial and commercial clients.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
